drugset
drugset / Trial / NCT05504395

A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome

NCT05504395 ↗

Phase 1 Completed 10 enrolled ConSynance Therapeutics
NaSingle-groupOpen-labelOther

Summary

The purpose of this Phase 1 study is to evaluate the pharmacokinetics (PK) and safety of a single dose of CSTI-500 10 mg in subjects with Prader-Willi syndrome (PWS) between 13 and 50 years of age with a genetically confirmed diagnosis of PWS.

Timeline

Start
2022-11-14
Primary completion
2023-02-21
Completion
2023-02-21

Drugs

EvaluationDrugModalityDoseRoute
Subject CSTI-500 Unknown 10 mg Oral

Indications

Prader-Willi syndrome